Zyversa Therapeutics Inc
ZVSA0.311USD
-0.238-43.30%
交易中 （美东）报价延迟15分钟
799.48K总市值
亏损市盈率 TTM
关于 Zyversa Therapeutics Inc 公司
ZyVersa Therapeutics, Inc. 是一家临床阶段专业生物制药公司。该公司专注于利用先进技术为患有慢性肾脏或炎症疾病的患者开发药物。其领先的肾脏候选药物胆固醇流出介质 VAR 200（2-羟丙基-β-环糊精或 2HBCD）正在开发中，用于治疗多种肾脏疾病。其领先的抗炎候选药物炎症小体 ASC 抑制剂 IC 100 是一种人源化单克隆抗体，正在开发中，用于治疗多种炎症疾病。其肾脏管线最初专注于罕见的慢性肾小球疾病。VAR 200 的主要适应症是局灶节段性肾小球硬化症 (FSGS)。VAR 200 的活性成分 2HBCD 由七个糖分子组成，它们结合在一起形成一个 3-D 环，具有疏水核心和亲水外部。 VAR 200 通过与肾小球膜的亲水成分相互作用，被动和主动介导胆固醇外流。
公司简介
公司代码ZVSA
公司名称Zyversa Therapeutics Inc
上市日期Dec 21, 2021
CEOMr. Stephen C. (Steve) Glover
员工数量7
证券类型Ordinary Share
年结日Dec 21
公司地址2200 N. Commerce Parkway
城市WESTON
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编33326
电话17542311688
网址https://www.zyversa.com/
公司代码ZVSA
上市日期Dec 21, 2021
CEOMr. Stephen C. (Steve) Glover
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
1.82K
--
Mr. Peter Wolfe
Mr. Peter Wolfe
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
127.00
--
Mr. Pablo A. Guzman, M.D.
Mr. Pablo A. Guzman, M.D.
Chief Medical Officer, Senior Vice President - Medical Affairs
Chief Medical Officer, Senior Vice President - Medical Affairs
76.00
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
--
--
Dr. Min Chul Park, Ph.D.
Dr. Min Chul Park, Ph.D.
Independent Director
Independent Director
--
--
Mr. James E. Sapirstein
Mr. James E. Sapirstein
Independent Director
Independent Director
--
--
Ms. Karen A. Cashmere
Ms. Karen A. Cashmere
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Robert G. (Rob) Finizio
Mr. Robert G. (Rob) Finizio
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
1.82K
--
Mr. Peter Wolfe
Mr. Peter Wolfe
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
127.00
--
Mr. Pablo A. Guzman, M.D.
Mr. Pablo A. Guzman, M.D.
Chief Medical Officer, Senior Vice President - Medical Affairs
Chief Medical Officer, Senior Vice President - Medical Affairs
76.00
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
--
--
Dr. Min Chul Park, Ph.D.
Dr. Min Chul Park, Ph.D.
Independent Director
Independent Director
--
--
Mr. James E. Sapirstein
Mr. James E. Sapirstein
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月28日 周三
更新时间: 5月28日 周三
持股股东
股东类型
持股股东
持股股东
占比
Armistice Capital LLC
5.85%
UBS Financial Services, Inc.
0.58%
Geode Capital Management, L.L.C.
0.45%
Virtu Americas LLC
0.36%
INCON Co., Ltd.
0.09%
Other
92.68%
持股股东
持股股东
占比
Armistice Capital LLC
5.85%
UBS Financial Services, Inc.
0.58%
Geode Capital Management, L.L.C.
0.45%
Virtu Americas LLC
0.36%
INCON Co., Ltd.
0.09%
Other
92.68%
股东类型
持股股东
占比
Hedge Fund
5.89%
Investment Advisor
0.58%
Investment Advisor/Hedge Fund
0.45%
Research Firm
0.36%
Corporation
0.09%
Individual Investor
0.04%
Other
92.59%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
35
361.22K
7.41%
+216.61K
2025Q1
36
361.22K
7.45%
+216.32K
2024Q4
37
136.78K
7.85%
+71.47K
2024Q3
62
57.46K
5.12%
-24.65K
2024Q2
59
16.60K
1.67%
-51.32K
2024Q1
59
17.73K
1.94%
-42.02K
2023Q4
64
48.48K
46.23%
+4.78K
2023Q3
64
46.91K
75.21%
+1.88K
2023Q2
61
49.59K
86.96%
+14.63K
2023Q1
50
16.17K
61.42%
-21.60K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Armistice Capital LLC
285.04K
5.85%
+285.04K
--
Mar 31, 2025
UBS Financial Services, Inc.
28.33K
0.58%
+24.14K
+576.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
21.71K
0.45%
+13.81K
+175.00%
Mar 31, 2025
Virtu Americas LLC
17.53K
0.36%
-7.73K
-30.61%
Mar 31, 2025
INCON Co., Ltd.
4.28K
0.09%
--
--
Dec 31, 2023
Tower Research Capital LLC
2.15K
0.04%
-1.33K
-38.13%
Mar 31, 2025
Glover (Stephen C)
1.82K
0.04%
--
--
Apr 15, 2025
Wolfe (Peter)
127.00
0%
--
--
Apr 15, 2025
BofA Global Research (US)
111.00
0%
+2.00
+1.83%
Mar 31, 2025
Guzman (Pablo A)
76.00
0%
--
--
Apr 15, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Nov 30, 2023
Merger
35<1
Nov 30, 2023
Merger
35<1
公告日期
类型
比率
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Mar 08, 2024
Merger
10<1
Nov 30, 2023
Merger
35<1
Nov 30, 2023
Merger
35<1
Nov 30, 2023
Merger
35<1
Nov 30, 2023
Merger
35<1
